Pharming Group Net Profit Margin 2013-2024 | PHGUF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Pharming Group net profit margin from 2013 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Pharming Group net profit margin from 2013 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$170.6B
Vertex Pharmaceuticals (VRTX)	$117.1B
Regeneron Pharmaceuticals (REGN)	$111.8B
Bristol Myers Squibb (BMY)	$109.9B
Gilead Sciences (GILD)	$104.8B
CSL (CSLLY)	$95.8B
GSK (GSK)	$79.5B
Alnylam Pharmaceuticals (ALNY)	$34.6B
Argenex SE (ARGX)	$32.5B
BioNTech SE (BNTX)	$28.5B
Biogen (BIIB)	$26.9B
Moderna (MRNA)	$23.5B
BeiGene (BGNE)	$22.7B
Illumina (ILMN)	$21.7B
Genmab (GMAB)	$15.5B
BioMarin Pharmaceutical (BMRN)	$12.9B
Incyte (INCY)	$12.9B
Vaxcyte (PCVX)	$12.4B
Exact Sciences (EXAS)	$12.3B
Insmed (INSM)	$12.3B
Bio-Techne Corp (TECH)	$11.7B
Sarepta Therapeutics (SRPT)	$11.3B
QIAGEN (QGEN)	$9.9B
Bio-Rad Laboratories (BIO.B)	$9.3B
Legend Biotech (LEGN)	$8.7B
Roivant Sciences (ROIV)	$8.3B
Ascendis Pharma (ASND)	$8.2B
Repligen (RGEN)	$7.8B
Revolution Medicines (RVMD)	$7.7B
Halozyme Therapeutics (HALO)	$7.7B